Skip to main content
Annals of Intensive Care

Table 1 Baseline patient characteristics

From: The effect of multidisciplinary extracorporeal membrane oxygenation team on clinical outcomes in patients with severe acute respiratory failure

 

Pre-ECMO team period (n = 70)

Post-ECMO team period (n = 46)

P value

Age (years)

61 (52–69)

60 (52–64)

0.672

Male

52 (74.3)

34 (73.9)

0.964

Body mass index (kg/m2)

23.1 (20.7–24.8)

23.8 (20.6–25.8)

0.163

Comorbidity

   

 Cardiovascular disease

7 (10.0)

5 (10.9)

>0.999

 Chronic renal failure

6 (8.6)

3 (6.5)

>0.999

 Asthma/COPD

12 (17.1)

2 (4.4)

0.039

 Liver cirrhosis

3 (4.3)

3 (6.5)

0.680

 Malignancy

  

0.052

  Solid tumor

18 (25.7)a

6 (13.0)b

 

  Hematologic malignancy

11 (15.7)c

5 (10.9)d

 

 Immunocompromised state

23 (32.9)

17 (37.0)

0.650

 Cardiac arrest before ECMO

8 (11.4)

10 (21.7)

0.134

Primary diagnosis

   

 Bacterial pneumonia

32 (45.7)

12 (26.1)

0.033

 Viral pneumonia

2 (2.9)

8 (17.4)

0.014

 Interstitial lung disease

15 (21.4)

5 (10.9)

0.141

 Trauma/burn

2 (2.9)

4 (8.7)

0.212

 Asphyxia

1 (1.4)

1 (2.2)

>0.999

 Othere

18 (25.7)

16 (34.8)

0.294

Severity score on the first day in the ICU

   

 APACHE II

18 (15–25)

25 (21–32)

<0.001

 SOFA

6 (4–9)

8 (6–14)

0.003

 RESP score

1 (−1 to 2)

0 (−2 to 2)

0.171

 PRESERVE score

5 (4–7)

6 (4–7)

0.664

  1. Values are given as the median (interquartile range) or n (%)
  2. APACHE II acute physiology and chronic health evaluation II, COPD chronic obstructive pulmonary disease, ECMO extracorporeal membrane oxygenation, ICU intensive care unit, PRESERVE predicting death for severe ARDS on VV-ECMO, RESP respiratory extracorporeal membrane oxygenation survival prediction, SOFA sequential organ failure assessment
  3. aMeningioma (n = 1), malignant mesothelioma (n = 1), lung (n = 10), esophageal (n = 2), liver (n = 2), and colon cancer (n = 2)
  4. bAcute myeloid leukemia (n = 3), acute lymphocytic leukemia (n = 1), chronic lymphocytic leukemia (n = 1), myelodysplastic syndrome (n = 4), and multiple myeloma (n = 2)
  5. cGlioma (n = 1), lung cancer (n = 2), colon cancer (n = 2), and non-seminomatous germ cell tumor (n = 1)
  6. dAcute myeloid leukemia (n = 1), multiple myeloma (n = 1), and lymphoma (n = 3)
  7. eOther includes radiation therapy-induced pneumonitis, pulmonary tuberculosis, diffuse alveolar hemorrhage, pulmonary alveolar proteinosis, and airway occlusion by tumor mass or blood clot
Back to article page